Investment management firm ARK Invest has made significant changes to its exchange-traded funds (ETFs) on Thursday, November 13, according to its daily fund disclosures. Notably, the firm decided to reduce its position in Advanced Micro Devices (AMD), a major player in the semiconductor industry. This move comes shortly after AMD showcased its latest advancements in artificial intelligence and data center operations during its Analyst Day on November 11, which garnered considerable attention and led to a surge in the stock price—up by approximately 10%. However, following the disclosure of these trades, AMD’s stock dropped by 4%, closing at $247.96.
ARK’s divestment included the sale of 87,051 AMD shares through the ARK Innovation ETF (ARKK), a transaction valued at around $22.5 million. This decision represents a strategic pivot away from one of the most popular chip stocks, possibly signaling that ARK is engaging in profit-taking after a recent rally.
In addition to AMD, ARK liquidated positions in several other companies. The firm sold 572,735 shares of Pinterest (PINS), equating to about $15.6 million, as well as 12,083 shares of Regeneron Pharmaceuticals (REGN) valued at approximately $8.2 million. Furthermore, ARK exited its position in Salesforce (CRM) by selling 21,974 shares, worth around $5.4 million.
Conversely, ARK Invest made substantial purchases in other sectors, signaling a commitment to expanding and diversifying its portfolio. The firm acquired 188,941 shares of Circle Internet Group (CRCL)—the largest issuer of the USDC stablecoin—across its Innovation, Next Generation Internet, and Fintech Innovation ETFs, amounting to roughly $16.3 million. This purchase follows a sizable investment made the previous day, reinforcing ARK’s confidence in Circle’s digital asset platform.
ARK also increased its exposure to cryptocurrency by purchasing 242,347 shares of Bitmine Immersion Technologies (BMNR) for about $9.8 million, further bolstering its investments in digital infrastructure.
In the biotechnology sector, ARK showed interest in gene-editing technologies by acquiring 140,193 shares of Beam Therapeutics (BEAM), valued at around $3.1 million. The firm has been active in building this position throughout the week. Additionally, ARK purchased 261,439 shares of Recursion Pharmaceuticals (RXRX) for about $1.2 million.
As these strategic moves unfold, analysts and investors will be keenly observing the performance of these stocks, particularly in light of ARK’s fluctuating investments and the rapidly evolving market landscape.
